| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||
Collaboration revenue | |||||||||
6,564 | - | - | - | - | - | - | - | - | - |
Grant revenues | |||||||||
- | - | - | 0 | 78 | 9 | 0 | - | - | - |
Sales | |||||||||
- | - | - | - | - | - | - | 0 | 12,605 | 15,253 |
Cost of sales | |||||||||
- | - | - | - | - | - | - | - | 9,919 | 8,427 |
Gross profit | |||||||||
- | - | - | - | - | - | - | 0 | 2,685 | 6,826 |
Operating expenses: | |||||||||
Selling expenses | |||||||||
- | - | - | - | - | - | - | - | 678 | - |
Research and development | |||||||||
4,004 | 4,667 | 5,822 | 101,679 | 47,261 | 4,071 | 3,862 | 489 | 423 | 240 |
General and administrative | |||||||||
4,863 | 4,352 | 2,440 | 4,140 | 6,765 | 1,737 | 219 | 2,064 | 5,471 | 6,617 |
Impairments | |||||||||
46,103 | 53,905 | - | - | - | - | - | - | - | - |
Recall charges | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Total operating expenses | |||||||||
54,970 | 62,924 | 8,262 | 105,819 | 54,026 | 5,808 | 4,081 | 2,553 | 6,572 | 6,858 |
Income (loss) from operations | |||||||||
-48,406 | -62,924 | -8,262 | -105,819 | -53,948 | -5,799 | -4,081 | -2,553 | -3,887 | -32 |
Other (expense) income: | |||||||||
Change in fair value of derivative liabilities | |||||||||
- | - | - | - | - | 5,730 | 192 | - | - | - |
Interest expense, net | |||||||||
-19 | -58 | -7 | - | - | - | - | - | - | - |
Interest income (expense), net | |||||||||
- | - | - | 126 | 180 | 96 | 2 | - | - | - |
Realized gain on marketable securities | |||||||||
- | - | - | - | - | 1,359 | 0 | - | - | - |
Other expense | |||||||||
- | - | 31 | 1 | 0 | 7 | 0 | - | - | - |
Gain on settlement of mortgage note receivable | |||||||||
- | 106 | - | - | - | - | - | - | - | - |
Loss on disposal of property and equipment | |||||||||
- | -60 | -100 | - | - | - | - | - | - | - |
Fair value of warrant liabilities in excess of proceeds from financing | |||||||||
- | - | - | - | - | 946 | 0 | - | - | - |
Loss on return of escrowed shares | |||||||||
- | - | - | 0 | -1,686 | -584 | 0 | 0 | - | - |
Impairment on mortgage note receivable | |||||||||
- | - | - | -1,177 | 0 | 0 | - | - | - | - |
Interest expense | |||||||||
- | - | - | - | - | - | - | -5,231 | -1,242 | -439 |
Change in fair value of derivative liabilities | |||||||||
256 | 306 | 907 | 2,603 | -9,916 | - | - | 153 | -281 | 0 |
Other income (expense), net | |||||||||
- | - | - | - | - | 5,648 | 194 | - | - | - |
Total other income (expense), net | |||||||||
237 | 294 | 769 | 1,551 | -11,422 | - | - | - | - | - |
Equity in loss of unconsolidated subsidiary | |||||||||
- | - | - | - | - | - | - | - | -42 | 55 |
Loss before income taxes | |||||||||
-48,169 | -62,630 | -7,493 | -104,268 | -65,370 | -151 | -3,887 | -7,631 | -5,454 | -415 |
Income tax benefit | |||||||||
- | -13,582 | -6,880 | -29,394 | -15,248 | -52 | 0 | 0 | 3 | -95 |
Loss from continuing operations | |||||||||
- | - | - | - | - | - | - | -7,631 | - | - |
Loss from discontinued operations, net of taxes | |||||||||
- | - | - | - | - | - | - | -333 | - | - |
Loss on sale of assets | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Net income (loss) | |||||||||
-48,169 | -49,048 | -613 | -74,874 | -50,122 | -99 | -3,887 | -7,964 | -5,457 | -319 |
Net loss | |||||||||
-48,169 | -49,048 | -613 | -74,874 | -50,122 | -99 | -3,887 | -7,964 | -5,457 | -319 |
Unrealized gain on marketable securities, net of tax | |||||||||
- | - | - | - | - | 236 | 0 | - | - | - |
Total comprehensive income (loss) | |||||||||
- | - | - | - | - | 137 | -3,887 | - | - | - |
Net loss per common share: | |||||||||
Net income (loss) per common share, basic and diluted | |||||||||
-1.51 | -1.75 | -0.03 | - | - | - | - | - | - | - |
Deemed dividend on preferred stock | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Net loss attributable to Biozone | |||||||||
- | - | - | - | - | - | - | -7,964 | - | - |
Loss per common share - continuing operations | |||||||||
- | - | - | - | - | - | - | -0.12 | - | - |
Loss per common share - discontinued operations | |||||||||
- | - | - | - | - | - | - | -0.01 | - | - |
Loss per share, basic | |||||||||
- | - | - | -3.18 | -2.40 | 0.00 | -0.07 | -0.13 | -0.11 | -0.01 |
Weighted average number of common shares outstanding, basic | |||||||||
- | - | - | 23,518 | 21,011 | 326,779 | 57 | - | - | - |
Loss per share, fully diluted | |||||||||
- | - | - | -3.30 | -2.40 | -0.01 | -0.07 | - | - | - |
Weighted average number of common shares outstanding, diluted | |||||||||
- | - | - | 23,533 | 21,011 | 327,753 | 57 | 61,631 | 50,443 | - |
Weighted average number of common shares outstanding, basic and diluted | |||||||||
31 | 28 | 24,126 | - | - | - | - | - | - | - |
Basic and diluted weighted average common shares outstanding | |||||||||
- | - | - | - | - | - | - | - | - | 44,749 |